Secondary analysis of 2,200 HeartMate 3 LVAD recipients in MOMENTUM 3: 2-year survival was 89.1% under 50 years, 86.3% at 50–59, 77.7% at 60–69 (HR 1.76) and 72.8% at ≥70 (HR 2.24). GI bleeding and sepsis rose with age; driveline infections fell.
Secondary analysisn = 2,200
Elad et al. Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial